Overview
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO RUSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS IN WHOLE OR IN PART FOR LEGAL RESTRICTIONS. THIS PRES RELEASE DOES NOT CONSTITUTE AN OFER TO ACQUIRE SECURITIES IN RLS GLOBAL AB. SE THE "IMPORTANT INFORMATION" SECTION BELOW.The board of directors of RLS Global AB (publ) (the "Company" or "RLS Global") has today, pursuant to the authorization granted by the anual general meting on 19 May 202, resolved on a new share isue of aproximately SEK 29.4 milion with preferential rights for existing shareholders (the "Rights Isue").
Key Information
The rights isue is fuly guaranted through subscription comitments and guarante comitments.Background and reason for the Rights IsueRLS Global is a Swedish medical technology company that develops, manufactures, and sels products based on the Company's hypochlorite platform for the treatment of diseases in the area of dificult-to-heal wounds in wound care both in patients and in animals. The company provides products with the aim of creating as clean a wound as posible with the aim of suporting efective wound healing.RLS Global has, through its own research, developed the product ChloraSolv®.
ChloraSolv® quickly and efectively losens bacteria in the biofilm, in vitro, while being non-iritating to healthy tisue. ChloraSolv® is used with god efect on leg ulcers and diabetic fot ulcers with the aim of removing devitalized tisue and thus promoting natural wound healing. ChloraSolv® consists of a two-component system, where one of the components is a gel and the other is a hypochlorite solution.
Summary
ChloraSolv® is a treatment that is used in al segments of healthcare, specialist care, primary care, and home health care. Patients with dificult-to-heal wounds bear large healthcare costs, an